Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lupus Clear all
Completed Phase 2 Interventional Results available

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

NCT01085084
View directory record Official record
Conditions
Lupus Arthritis
Interventions
Laquinimod, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BLYS and IFN in SLE

NCT00611611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
fluzone, pneumovax
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Not applicable Interventional

Lupus Intervention for Fatigue Trial

NCT02653287
View directory record Official record
Conditions
Fatigue, Physical Activity, Lupus Erythematosus, Systemic
Interventions
Experimental, Control
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

NCT01753193
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Anifrolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 68 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Palma, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting Phase 1 Interventional

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

NCT07237659
View directory record Official record
Conditions
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Interventions
NTR1011
Drug
Lead sponsor
Neutrolis
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Apple Valley, California • Beverly Hills, California • Covina, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Cutaneous Lupus Medication Experience Study

NCT02176148
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
fluocinonide 0.05% cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional

Balancing Lupus Experiences With Stress Strategies

NCT01351662
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Arthritis Self Management Program
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

NCT04835441
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ALPN-101, Placebo
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480
View directory record Official record
Conditions
SLE
Interventions
Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
48
States / cities
Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting Phase 1 Interventional

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Budoprutug
Drug
Lead sponsor
Climb Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Allen, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-CD20 in Systemic Lupus Erythematosus

NCT00036491
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

NCT03393013
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Upland, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

NCT05337124
View directory record Official record
Conditions
Lupus Nephritis
Interventions
LUPKYNIS
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
South Gate, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1 Interventional

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

NCT02537028
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
MSC2364447C, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Anniston, Alabama • El Cajon, California • Lakewood, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Jul 22, 2026, 8:30 AM EDT
Not listed Phase 1 Interventional

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

NCT03878303
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AC0058TA, Placebo AC0058TA
Drug
Lead sponsor
ACEA Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

NCT00094380
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CTLA4-IgG4m (RG2077), Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)

NCT02176486
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Ixazomib, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
La Jolla, California • Upland, California • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting No phase listed Observational

Research Accelerated by You Lupus Registry

NCT06927219
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
Interventions
Not listed
Lead sponsor
Lupus Foundation of America
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

NCT05856448
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

NCT03152058
View directory record Official record
Conditions
High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
Interventions
Certolizumab Pegol
Drug
Lead sponsor
David Ware Branch
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 8:30 AM EDT